Britannia Life Sciences Inc
F:L020
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2.2), the stock would be worth €0.11 (159% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.8 | €0.04 |
0%
|
| 3-Year Average | 2.2 | €0.11 |
+159%
|
| 5-Year Average | 2.6 | €0.13 |
+211%
|
| Industry Average | 4.3 | €0.21 |
+404%
|
| Country Average | 2.7 | €0.13 |
+214%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
B
|
Britannia Life Sciences Inc
F:L020
|
14.6m EUR | 0.8 | 1.3 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
301B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 1 319.4 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
101.6B ZAR | 1.1 | 10.5 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.1B USD | 1 961.7 | 38 458.7 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
56.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.1B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
32.4B EUR | 7.8 | 174.4 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.8B USD | 53.9 | -3 291.8 | |
| US |
Q
|
Qnity Electronics Inc
NYSE:Q
|
30.1B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
Britannia Life Sciences Inc
Glance View
Britannia Life Sciences, Inc. is a global product development platform. The company is headquartered in Toronto, Ontario. The company went IPO on 2017-12-01. The firm's platform offers an integrated suite of services to assist companies along their product development journey. The firm provides product formulations, safety assessments, analytical and microbiological testing, global compliance and consumer evaluations to the cosmetic, consumer packaged goods and nutraceutical industries in the United Kingdom and globally. The company is also engaged in the development and regulatory approval of topical and edible cannabis products, including preparation and support for food authorizations. The company serves consumer packaged goods (CPG), cosmetics, household goods and nutraceutical industries, blue-chip, food and beverage, nutraceutical sectors, toiletries, small and medium enterprise (SME) clients.
